trial

The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients

NCTId NCT01186471
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Early Phase 1 · Completed
Enrollment 32 (actual)
Sponsored by Janssen, L.P. - Investigator Initiated Studies Program
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Early Phase 1
Status
Completed
Enrollment
32 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2010-05
Primary completion
—
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
A643 (nicotine)

Sponsors

Janssen, L.P. - Investigator Initiated Studies ProgramLead Sponsor
Agentschap voor Innovatie door Wetenschap en TechnologieCollaborator

Sites

0 total

Facts & assertions

3 sourced
Enrollment
32
Phase
EARLY_PHASE1
Status
COMPLETED
relationships
The graph out of here
drug
A643 (nicotine)
drug
lead_sponsor
Janssen, L.P. - Investigator Initiated Studies Program
company
collaborator
Agentschap voor Innovatie door Wetenschap en Technologie
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognition Disorders
indication